Patent application number | Description | Published |
20090287762 | BLENDING SINGLE-MASTER AND MULTI-MASTER DATA SYNCHRONIZATION TECHNIQUES - Architecture that maintains the user experience as close as possible to the user experience when dealing with the usual/regular forms and data provided in an office application when dealing with hybrid forms and hybrid data. Synchronization of the hybrid data to single-master and multi-masters systems is accomplished when the associated hybrid client goes offline, changes are made to the hybrid data, and then the client comes back online. For example, where the single-master system is a line-of-business (LOB) server system and the multi-master system is an officer server that employs collaboration capability, the architecture allows office users to access, manipulate, and share LOB entity information using collaborative means, while at the same time, ensuring data and business process consistency for the LOB entity in the LOB system. | 11-19-2009 |
20140164489 | BLENDING SINGLE-MASTER AND MULTI-MASTER DATA SYNCHRONIZATION TECHNIQUES - Architecture that maintains the user experience as close as possible to the user experience when dealing with the usual/regular forms and data provided in an office application when dealing with hybrid forms and hybrid data. Synchronization of the hybrid data to single-master and multi-masters systems is accomplished when the associated hybrid client goes offline, changes are made to the hybrid data, and then the client comes back online. For example, where the single-master system is a line-of-business (LOB) server system and the multi-master system is an officer server that employs collaboration capability, the architecture allows office users to access, manipulate, and share LOB entity information using collaborative means, while at the same time, ensuring data and business process consistency for the LOB entity in the LOB system. | 06-12-2014 |
Patent application number | Description | Published |
20110052689 | SUSTAINED RELEASE OF GUAIFENESIN - The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1: 1) to about nine-to-one (9: 1), more preferably a range of about three-to-two (3:2) to about six-to-one (6: 1), and most preferably in a range of about two-to-one (2: 1) to about four-to-one (4: 1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. | 03-03-2011 |
20120213847 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 08-23-2012 |
20130334122 | MICROPOROUS ZIRCONIUM SILICATE AND ITS METHOD OF PRODUCTION - The present invention relates to novel microporous zirconium silicate compositions having a desired particle size distribution and methods of making those compositions. These compositions have an ideal particle size distribution for use ex vivo, for example in a dialysis exchange cartridge, yet retain many of the desirable properties of prior improved absorbers including high cation exchange capacity. Further, the new zirconium silicate molecular sieve absorbers can be manufactured using a technique that achieves the desired particle size distribution while eliminating the screening step that was previously necessary. | 12-19-2013 |
20140044785 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 02-13-2014 |
20140105971 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA IN HYPERCALCEMIC PATIENTS AND IMPROVED CALCIUM-CONTAINING COMPOSITIONS FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel calcium-containing microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without removing calcium from the patient's body. Also disclosed are methods of using calcium-free or low calcium microporous zirconium silicate compositions for the treatment of hyperkalemia in patients also suffering from hypercalcemia. | 04-17-2014 |
20140113002 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 04-24-2014 |
20140287060 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 09-25-2014 |
20140302175 | MICROPOROUS ZIRCONIUM SILICATE AND DIURETICS FOR THE REDUCTION OF POTASSIUM AND TREATMENT OF CHRONIC KIDNEY AND/OR CHRONIC HEART DISEASE - The present invention relates to novel methods of using microporous zirconium silicate to reduce the risk of hyperkalemia and to lower aldosterone levels in the treatment of chronic kidney disease and/or chronic heart disease with therapies comprising diuretics. The invention provides a safe way to reduce the risk of hyperkalemia and to lower aldosterone. The invention also relates to treatment of other conditions that can occur either alone or in connection with hyperkalemia, chronic kidney disease, and/or chronic heart disease. | 10-09-2014 |
20140342017 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 11-20-2014 |
20140377359 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 12-25-2014 |
20140377560 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 12-25-2014 |
20150196592 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patent. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 07-16-2015 |
20150225249 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 08-13-2015 |
Patent application number | Description | Published |
20090209912 | Apparatus for peripheral vascular access - This invention provides devices and methods for insertion of a catheter into a vessel. The devices include coaxial slidably mounted needle, dilator and catheter components. The methods include piercing a vessel with the needle component, dilating the pierced hole with the dilator component, retraction of the needle component, insertion of the catheter and withdrawal of the dilator. | 08-20-2009 |
20120150118 | Apparatus for Peripheral Vascular Access - This invention provides devices and methods for insertion of a catheter into a vessel. The devices include coaxial slidably mounted needle, dilator and catheter components. The methods include piercing a vessel with the needle component, dilating the pierced hole with the dilator component, retraction of the needle component, insertion of the catheter and withdrawal of the dilator. | 06-14-2012 |
20130204226 | Pressure Actuated Catheter Valve - This invention provides catheter assemblies and methods for insertion of a catheter into a vessel. The assemblies include a resilient valve in the hub of the catheter that can be opened by pressure from a male luer fitting. The methods include piercing a vessel with the needle and catheter of the assembly, retraction of the needle component thus closing the resilient valve. Finally the catheter can be accessed by applying a male luer fitting to the catheter hub and a shoulder of the resilient valve. | 08-08-2013 |
20140058357 | Apparatus for Peripheral Vascular Access - This invention provides devices and methods for insertion of a catheter into a vessel. The devices include coaxial slidably mounted needle, dilator and catheter components. The methods include piercing a vessel with the needle component, dilating the pierced hole with the dilator component, retraction of the needle component, insertion of the catheter and withdrawal of the dilator. | 02-27-2014 |
Patent application number | Description | Published |
20100316727 | TREATMENT OF INFLAMMATORY DISORDERS WITH OZONE - Methods for therapeutic treatment of inflammatory conditions in a mammalian patient provide clinical benefits including reduction of inflammation, vasorelaxation, reduction in edema and increased blood flow, the methods generally comprising extracorporeal treatment of blood, blood fractionate, or other biological fluid to expose such fluids to a precise, measured amount of ozone to produce a blood or biological fluid having a quantified absorbed dose of ozone, and reinfusing the treated biological fluid to the patient to provide therapeutic effects beneficial in the treatment of inflammatory disorders and related symptoms or conditions. | 12-16-2010 |
20100316730 | TREATMENT OF CARDIOVASCULAR DISEASES WITH OZONE - Methods of treating cardiovascular diseases, including atherosclerosis, peripheral arterial occlusive disease, congestive heart failure, hypertension, cerebrovascular disease, dyslipidemia and vasospastic disorders such as Raynaud's disease, in a mammalian patient involve extracorporeally subjecting an amount of blood, blood fractionate or other biological fluid from a patient to a measured amount of ozone delivered by an ozone delivery system, resulting in the absorption of a quantifiable absorbed-dose of ozone and reinfusing the treated fluid into the patient to therapeutically treat cardiovascular disease and related conditions. | 12-16-2010 |
20100318014 | TREATMENT OF ACUTE ISCHEMIC BRAIN STROKE WITH OZONE - Methods are provided for treatment of acute ischemic brain stroke based on the delivery of a measured amount of ozone to a sample of a mammalian patient's blood, blood fractionate or other biological fluid through the use of an ozone delivery system. The ozone-treated fluid, having absorbed a quantifiable absorbed-dose of ozone, is subsequently reinfused into the same patient and the autologous blood sample provides therapeutic effects to the patient, such as reduction in edema associated with the ischemic penumbra, improvement in impaired blood flow to the area surrounding the infarct, relaxation of the vascular endothelium and reduction of inflammation. | 12-16-2010 |
20110031172 | Ozone Delivery System Including Gas-Fluid Contacting Devices And Methods Of Use - An ozone delivery system for delivering and manufacturing a measured amount of an ozone/oxygen admixture, which is able to measure, control, report and differentiate between delivered-ozone and absorbed-dose of ozone. Improved gas-fluid contacting devices that maximize gas-fluid mass transfer may be included. All gas contacting surfaces of the system, including one or more gas-fluid contacting devices are made from ozone-inert construction materials that generally do not absorb ozone or introduce amounts of contaminants or deleterious byproducts of oxidation into a fluid or non-fluid target from ozone oxidation. | 02-10-2011 |
20110031190 | Ozone Delivery System Including Gas-Fluid Contacting Devices And Methods Of Use - An ozone delivery system for delivering and manufacturing a measured amount of an ozone/oxygen admixture, which is able to measure, control, report and differentiate between delivered-ozone and absorbed-dose of ozone. Improved gas-fluid contacting devices that maximize gas-fluid mass transfer may be included. All gas contacting surfaces of the system, including one or more gas-fluid contacting devices are made from ozone-inert construction materials that generally do not absorb ozone or introduce amounts of contaminants or deleterious byproducts of oxidation into a fluid or non-fluid target from ozone oxidation. | 02-10-2011 |